Advisory Research’s Immunocore IMCR Stock Holding History

Advisory Research’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,276	Closed	-$1.31M	–	394
2023 Q3	$1.31M	Buy	25,276 +812	+3%	+$48.1K	0.18%	156
2023 Q2	$1.47M	Buy	24,464 +4,073	+20%	+$232K	0.19%	155
2023 Q1	$1.01M	Sell	20,391 -1,010	-5%	-$56.8K	0.17%	154
2022 Q4	$1.22M	Sell	21,401 -5,770	-21%	-$325K	0.11%	130
2022 Q3	$1.27M	Buy	+27,171	New	+$1.29M	0.12%	128

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Advisory Research's IMCR Position: Q4 2023 in Review

Advisory Research sold out of Immunocore (IMCR) in Q4 2023, closing a stake of 25,276 shares — an estimated $1.31M sold.

Advisory Research first reported a position in IMCR in Q3 2022 and held it in 5 quarters. The position peaked at $1.47M in Q2 2023. 133 funds tracked by Wall St. Rank hold IMCR as of Q4 2023.

Advisory Research reported no remaining Immunocore position as of Q4 2023 after selling out during the quarter.
Advisory Research sold 25,276 Immunocore shares in Q4 2023, an estimated $1.31M.
Advisory Research first reported a position in Immunocore in Q3 2022 and held it in 5 quarters.
Advisory Research's Immunocore position peaked at $1.47M in Q2 2023.
133 funds tracked by Wall St. Rank held Immunocore as of Q4 2023.

Based on Advisory Research's 13F filing for Q4 2023, filed 13 Feb 2024.